Reaction Biology Europe GmbH – Trademark Portfolio
Entity Type: 27
Reaction Biology Europe GmbH holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include PROQINASE, SUBQPERIOR, and 33PANQINASE.
Engesserstr. 4
79108 Freiburg
Showing of trademarks Trademarks
Trademark Classifications
Reaction Biology Europe GmbH's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Reaction Biology Europe GmbH have?
Reaction Biology Europe GmbH has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does Reaction Biology Europe GmbH file in?
Reaction Biology Europe GmbH files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Reaction Biology Europe GmbH's most well-known trademarks?
Reaction Biology Europe GmbH's registered trademark portfolio includes well-known marks such as PROQINASE, SUBQPERIOR, and 33PANQINASE. These are among 3 currently registered trademarks in the portfolio.
What is Reaction Biology Europe GmbH's trademark registration success rate?
Reaction Biology Europe GmbH has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.